跳至主要内容
临床试验/NCT03302325
NCT03302325已完成不适用

Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC

Medical University of South Carolina1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2017年10月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.

研究概览

简要总结

  1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.
  2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.

详细描述

The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains information that determines in part the traits, such as eye color, height, or disease risk, that are passed on from parent to child. This reaction will be measured by studying patient blood that will be collected before and during treatment until there is disease progression.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors (including lymphoma)
  • Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3
  • Life expectancy ≥ 3 months
  • Patients must be able to provide consent
  • Patients can be enrolled in other interventional clinical trials

排除标准

  • Age < 18-year-old

结局指标

主要结局

Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.

时间窗: 24 months

Changes in patients' ctDNA longitudinal samples through treatment, and when available, of primary tumor and metastasis.

时间窗: 24 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验